It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite advances in allogeneic hematopoietic cell transplantation, acute graft-versus-host disease (aGVHD) remains its leading complication, yet with heterogeneous outcomes. Here, we analyzed aGVHD phenotypes and clinical classifications in depth in large, multicenter cohorts involving 3019 patients and addressed prevailing gaps by developing data-driven models. We compared, tested and verified these along with all conventional classifications in independent cohorts and found that data-driven grading outperformed conventional grading in Akaike information criterion and concordance index metrics. Data-driven classifications refined aGVHD assessment with up to 12 severity grades, which were associated with distinct nonrelapse mortality (NRM) and confirmed the key role of intestinal aGVHD. We developed an online calculator for physicians to implement principal component-derived grading (PC1). These results provide substantial insight into the evaluation of aGVHD phenotypes and multiorgan involvement, which relegates the exclusive reporting of overall aGVHD severity grades in transplant registries and clinical trials. Data-driven aGVHD grading provides an expandable platform to refine classification and transplant risk assessment.
Acute GVHD severity grading is based on target organ assessments. Here, the authors show that data-driven grading can identify 12 distinct grades with specific aGVHD phenotypes, which are associated with clinical outcomes, and that their method outperformed conventional gradings.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 University Hospital Essen, Computational Hematology Lab, West-German Cancer Center, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331); University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West-German Cancer Center, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331); TU Dortmund University of Applied Sciences, Chair III of Applied Mathematics, Dortmund, Germany (GRID:grid.5675.1) (ISNI:0000 0001 0416 9637)
2 University Hospital Essen, Computational Hematology Lab, West-German Cancer Center, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331); University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West-German Cancer Center, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331)
3 University Medical Center Hamburg-Eppendorf (UKE), Department for Stem Cell Transplantation, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484)
4 Hannover Medical School, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
5 Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
6 University Hospital Heidelberg, Department of Internal Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
7 University of Bologna, Department of Medical and Surgical Sciences- DIMEC, Applied Physics and Biophysics group, Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758)
8 University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West-German Cancer Center, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331); Partner sites Essen/Düsseldorf, German Cancer Consortium (DKTK), Essen, Germany (GRID:grid.410718.b); Partner site Essen, Cancer Research Center Cologne Essen (CCCE), Essen, Germany (GRID:grid.410718.b)
9 University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West-German Cancer Center, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331); Partner sites Essen/Düsseldorf, German Cancer Consortium (DKTK), Essen, Germany (GRID:grid.410718.b)
10 University Hospital Essen, Computational Hematology Lab, West-German Cancer Center, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331); University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West-German Cancer Center, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331); Partner sites Essen/Düsseldorf, German Cancer Consortium (DKTK), Essen, Germany (GRID:grid.410718.b); Partner site Essen, Cancer Research Center Cologne Essen (CCCE), Essen, Germany (GRID:grid.410718.b); Ruhr-University Bochum, Department of Hematology and Oncology, Marienhospital University Hospital, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X); University Hospital Essen, Institute for Experimental Cellular Therapy, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331)